Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($6.95) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00), FiscalAI reports.
Ernexa Therapeutics Stock Down 4.2%
Ernexa Therapeutics stock traded down $0.32 during mid-day trading on Monday, hitting $7.21. The company had a trading volume of 483,898 shares, compared to its average volume of 912,916. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $100.46. The business has a fifty day moving average of $5.89 and a 200 day moving average of $21.13. The stock has a market cap of $8.44 million, a price-to-earnings ratio of -0.10 and a beta of 1.88.
Analyst Upgrades and Downgrades
ERNA has been the subject of a number of analyst reports. Brookline Capital Markets initiated coverage on Ernexa Therapeutics in a research report on Thursday. They set a “buy” rating and a $30.00 price objective for the company. Wall Street Zen raised Ernexa Therapeutics to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ernexa Therapeutics has an average rating of “Hold” and a consensus price target of $30.00.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is currently owned by hedge funds and other institutional investors.
About Ernexa Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.
Featured Articles
- Five stocks we like better than Ernexa Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}
